Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

doi:10.1097/JTO.0b013e3181913e28

Article

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2009

Lim Elaine H, Zhang Shen-Li, Li Jia-Liang, Yap Wee-See, Howe Tse-Chiang, Tan Bien-Peng, Lee Yong-Shyan, Wong Daniel, Khoo Kay-Leong, Seto Kar-Yin, Tan Lenny, Agasthian Thirugananam, Koong Heng-Nung, Tam John, Tan Christie, Caleb Michael, Chang Alex, Ng Alan, Tan Patrick

Abstract excerpt

BACKGROUND: Progression of non-small cell lung cancer (NSCLC) from early- to late-stage may signify the accumulation of gene mutations. An advanced-stage tumor's mutation profile may also have prognostic value, guiding treatment decisions. Mutation detection of multiple genes is limited by the lo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Abstract excerpt

Topics

Related research